Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
Favorable long-term, open-label treatment data from nearly 500 patients in real-world setting suggest that patient-tailored, as-needed administrations of fasedienol over time were safe and... | June 1, 2023
United States Shawn Singh American Society For Clinical Psychopharmacology American Society Clinical Psychopharmacology Clinician Global Impression
Source: marketscreener.com